期刊
MOLECULAR GENETICS AND METABOLISM
卷 135, 期 1, 页码 15-26出版社
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.ymgme.2021.12.005
关键词
Creatine deficiency syndromes; SLC6A8; GAMT, AGAT; Creatine treatment; Gene therapy
资金
- Swiss National Science Foundation [31003A-175778]
- Swiss National Science Foundation (SNF) [31003A_175778] Funding Source: Swiss National Science Foundation (SNF)
Creatine deficiency syndromes are inherited metabolic disorders that mainly affect the central nervous system. Current treatment strategies can benefit some patients, but for others, the development of novel therapies is necessary for more effective treatment options.
Creatine deficiency syndromes (CDS) are inherited metabolic disorders caused by mutations in GATM, GAMT and SLC6A8 and mainly affect central nervous system (CNS). AGAT- and GAMT-deficient patients lack the functional brain endogenous creatine (Cr) synthesis pathway but express the Cr transporter SLC6A8 at blood-brain barrier (BBB), and can thus be treated by oral supplementation of high doses of Cr. For Cr transporter deficiency (SLC6A8 deficiency or CTD), current treatment strategies benefit one-third of patients. However, as their phenotype is not completely reversed, and for the other two-thirds of CTD patients, the development of novel more effective therapies is needed. This article aims to review the current knowledge on Cr metabolism and CDS clinical aspects, highlighting their current treatment possibilities and the most recent research perspectives on CDS potential therapeutics designed, in particular, to bring new options for the treatment of CTD. (c) 2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据